Technical Analysis for GLYC - GlycoMimetics, Inc.

Grade Last Price % Change Price Change
grade C 12.97 -0.99% -0.13
GLYC closed down 0.99 percent on Friday, March 22, 2019, on 1.2 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical GLYC trend table...

Date Alert Name Type % Chg
Mar 22 200 DMA Resistance Bearish 0.00%
Mar 22 Shooting Star Candlestick Bearish 0.00%
Mar 22 Stochastic Sell Signal Bearish 0.00%
Mar 22 NR7 Range Contraction 0.00%
Mar 22 Overbought Stochastic Strength 0.00%
Mar 21 Upper Bollinger Band Walk Strength -0.99%
Mar 21 Overbought Stochastic Strength -0.99%
Mar 21 Up 3 Days in a Row Strength -0.99%
Mar 21 Up 4 Days in a Row Strength -0.99%
Mar 21 Up 5 Days in a Row Strength -0.99%

Older signals for GLYC ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
Health Biotechnology Pharmaceutical Industry Diseases Chemotherapy Drug Discovery Clinical Trial Acute Myeloid Leukemia Design Of Experiments Product Testing Pseudomonas Hematologic Cancers Nursing Research Sickle Cell Disease
Is GLYC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 19.2
52 Week Low 8.29
Average Volume 223,843
200-Day Moving Average 13.1965
50-Day Moving Average 11.4246
20-Day Moving Average 12.0685
10-Day Moving Average 12.275
Average True Range 0.512
ADX 19.17
+DI 27.7656
-DI 16.4855
Chandelier Exit (Long, 3 ATRs ) 11.704
Chandelier Exit (Short, 3 ATRs ) 11.976
Upper Bollinger Band 13.2467
Lower Bollinger Band 10.8903
Percent B (%b) 0.88
BandWidth 19.52521
MACD Line 0.3814
MACD Signal Line 0.2613
MACD Histogram 0.1201
Fundamentals Value
Market Cap 424.42 Million
Num Shares 32.7 Million
EPS -1.34
Price-to-Earnings (P/E) Ratio -9.68
Price-to-Sales 18873.21
Price-to-Book 3.02
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.44
Resistance 3 (R3) 13.47 13.36 13.36
Resistance 2 (R2) 13.36 13.24 13.34 13.33
Resistance 1 (R1) 13.16 13.17 13.11 13.13 13.31
Pivot Point 13.05 13.05 13.02 13.03 13.05
Support 1 (S1) 12.85 12.93 12.80 12.82 12.63
Support 2 (S2) 12.74 12.86 12.72 12.61
Support 3 (S3) 12.54 12.74 12.58
Support 4 (S4) 12.51